Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OSU 6162

Drug Profile

OSU 6162

Alternative Names: Movement disorder therapeutics - Pfizer; PNU-9639; PNU-96391; PNU-96391A

Latest Information Update: 22 May 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Carlsson Research AB
  • Developer Carlsson Research AB; NeuroSearch; Pfizer
  • Class Antipsychotics; Piperidines; Small molecules; Sulfones
  • Mechanism of Action Dopamine D2 receptor modulators; Dopamine D2 receptor partial agonists; Serotonin 2 receptor modulators; Serotonin 2A receptor partial agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic fatigue syndrome; Stroke
  • Discontinued Parkinson's disease

Most Recent Events

  • 11 Jul 2017 Oslo University Hospital plans a phase II trial for Fatigue (secondary to aneurysmal subarachnoid haemorrhage) in Norway (NCT03209830)
  • 20 Mar 2017 Phase-II clinical trials in Stroke in Sweden (PO) (EudraCT2016-003888-19)
  • 04 Feb 2016 OSU 6162 is still in phase II trials for Chronic fatigue syndrome in Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top